TrialJournal for immunotherapy of cancer2019

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Geoffrey T Gibney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.